Intellia Therapeutics, Inc. (NTLA) vs Septerna, Inc. (SEPN)
Intellia Therapeutics, Inc. and Septerna, Inc. are both Biotechnology companies. Intellia Therapeutics, Inc. and Septerna, Inc. are of similar size ($1.8B and $1.7B). Septerna, Inc. grew revenue faster over the last twelve months: 13,520.1% against 12.6%. Septerna, Inc. has the higher net margin (−24.5% vs −672.2%) and the lower return on invested capital (−189.0% vs −91.3%). Across the 15 metrics below, Septerna, Inc. leads on 11 and Intellia Therapeutics, Inc. on 4.
Valuation
Profitability
| Metric | NTLA | SEPN | Biotechnology median |
|---|---|---|---|
| Gross margin | 100.00% | 100.00% | 65.16% |
| Operating margin | (711.66%) | (44.04%) | 0.00% |
| Net margin | (672.16%) | (24.51%) | 0.00% |
| Free cash flow margin | (585.82%) | 118.93% | 0.00% |
| Return on equity | (55.44%) | (6.34%) | (57.72%) |
| Return on assets | (45.55%) | (4.94%) | (49.22%) |
| Return on invested capital | (91.28%) | (189.01%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack